Abstract

Methods and kits for mitigating lung injury in a subject treated with a targeted radiation therapy or otherwise exposed to radiation are described. In particular, an effective amount of a thrombopoietin mimetic, such as RWJ-800088 or romiplostim, is used to mitigate the radiation-induced lung injury.

IPC Classes  ?

• A61K 38/19 - CytokinesLymphokinesInterferons
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61N 5/00 - Radiation therapy
• A61P 35/00 - Antineoplastic agents

Abstract

Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (CMA), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and/or antagonizing activity of retinoic acid receptor alpha (RARα) in subjects in need thereof.

IPC Classes  ?

• C07C 279/22 - Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
• C07D 265/36 - 1,4-OxazinesHydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
• C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Provided herein are methods of determining a subject's level of exposure to radiation and methods of determining a subject's risk of subsequent development of radiation disease or risk of poor prognosis from radiation exposure that include determining a level of one or more miRNAs selected from the group consisting of mouse and human homologues of mouse miR-130a-3p, miR-150-5p, miR-17-3p, miR-187-3p, miR-194-5p, miR-27a-3p, miR-30a-3p, miR-30c-5p, miR-142-5p, miR-342-3p, miR-34b-3p, miR-126- 3p, miR-320-3p, miR-136-5p, miR-33-5p, miR-142a-3p, miR-706, miR-375-3p, miR-29a- 5p, miR-193a-3p, miR-99b-5p, miR-151-3p, miR-let-7d-3p, miR-486-5p, miR-423-5p, miR-30b-5p, miR-191-5p, miR-497a-5p, miR-32-5p, miR-214-5p, miR-326-3p, miR-1195, miR-122-5p, miR-1839-3p, miR-500-3p, miR-30e-3p, miR-322-3p, miR-709, miR-486-3p, miR-133a-3p, miR-676-3p, miR-744-5p, miR-29a-3p, miR-1839-5p, miR-30a-5p, miR- 199b-5p, miR-125a-5p, miR-133b-3p, miR-24-3p, miR-21a-5p, miR-503-5p, miR-328-3p, miR-let-7g-5p, miR-362-3p, miR-199a-5p, miR-15a-3p, miR-139-5p, miR-149-5p, miR- 29b-3p, miR-la-3p, miR-23b-3p, miR-215-5p, miR-204-5p, miR-200b-5p, miR-25-3p, miR-338-3p, and miR-196b-5p, in a sample including a biological fluid from the subject.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A01H 1/06 - Processes for producing mutations, e.g. treatment with chemicals or with radiation
• A61B 6/08 - Auxiliary means for directing the radiation beam to a particular spot, e.g. using light beams
• A61B 18/18 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
• A61M 36/04 - Arrangements specially adapted for placing, e.g. inhaling or injecting, radioactive material within the body
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The invention provides mycobacterial plasmids expressing antigens and immunogenic compositions comprising these plasmids, methods for quality control of such compositions, and their use in immunization methods.

IPC Classes  ?

• A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 1/20 - BacteriaCulture media therefor
• A61P 37/04 - Immunostimulants
• C12N 15/09 - Recombinant DNA-technology
• C12R 1/32 - Mycobacterium

Abstract

Humanized Antibodies to SEB, fragments thereof, and compositions comprising such are provided. Therapies for staphylococcal infections and diseases are also provided. The presently claimed invention was made by or on behalf of the below listed parties to a joint research agreement. The joint research agreement was in effect on or before the date the claimed invention was made and the claimed invention was made as a result of activities undertaken within the scope of the joint research agreement.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

Methods are disclosed for treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) using inhibition of p21 protein (Cdc42/Rac)-activated kinase (PAK1).

IPC Classes  ?

• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

Methods are provided for determining if a subject is likely to develop an age-related disease based on miRNA signatures. Related methods of treatment are also provided.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

Provided are methods of treating an autoimmune disease in a subject, or of suppressing transplant rejection in a subject, or of treating a cancer in a subject, as well as compositions therefor.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

The present invention provides biomarkers, methods and kits for diagnosing active tuberculosis in a subject, methods and kits for monitoring the effectiveness of treatment for active TB, as well as methods for identifying a compound that can treat TB reduce or inhibit the development of complications associated with the disease in a subject, and methods to treat active TB.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention is directed to compositions and methods related to proteins that are physically associated with ceramide-like glycolipids for use as activators of NKT cells. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.

IPC Classes  ?

• C07H 15/18 - Acyclic radicals, substituted by carbocyclic rings
• A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 33/00 - Antiparasitic agents
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

Isolated polypeptides comprising a mutant programmed cell death 1 (PD-1) polypeptide and fusion polypeptides comprising an isolated mutant PD-1 polypeptide fused to an immunoglobulin domain polypeptide are provided. Further provided are methods of using a composition comprising the fusion polypeptide for stimulating T cell activation for treating disorders including a tumor or an infection.

IPC Classes  ?

• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/00 - Medicinal preparations containing peptides
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Abstract

Methods and systems for identifying inhibitors of Equilibrative Nucleoside Transporters are provided. Methods and systems for identifying inhibitors of Concentrative Nucleoside Transporters are also provided.

IPC Classes  ?

• C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

Methods are provided for identifying an agent as a selective inhibitor of a Bcl-2-associated x-protein (BAX).

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C07K 1/00 - General processes for the preparation of peptides
• C07K 2/00 - Peptides of undefined number of amino acidsDerivatives thereof
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

Methods and systems for high-throughput Identification of receptor: ligand interactions are provided. Throughout this application various publications are referred to in parentheses. Full citations for these references may be found at the end of the specification. The disclosures of these publications, and all patents, patent application publications and books referred to herein, are hereby incorporated by reference in their entirety into the subject application to more fully describe the art to which the subject invention pertains.

IPC Classes  ?

• C40B 30/06 - Methods of screening libraries by measuring effects on living organisms, tissues or cells

Abstract

Methods are disclosed for treating and preventing gut barrier dysfunction or an illness associated with gut barrier dysfunction in a subject comprising administering to the subject bacterium that produce an indole or an indole metabolite and for identifying compounds and bacteria for use in treatment and prevention of gut barrier dysfunction or an illness associated with gut barrier dysfunction.

IPC Classes  ?

• C07D 211/56 - Nitrogen atoms
• C07D 211/92 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom

Abstract

Methods and products are provided for producing an artery-specific endothelial cell. Also provided are methods for treating a tumor in a subject.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C07K 14/475 - Growth factorsGrowth regulators

Abstract

Methods are provided for diagnosing and treating a blood cancer or a myelodysplastic syndrome in a subject. Associated compositions and kits therefor are also provided.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Provided are compositions comprising a plurality of isolated mycobacterium membrane vesicles, and methods of use thereof, and methods of improving the efficacy of immunizations. Throughout this application various publications are referred to by number in parentheses. Full citations for the references may be found at the end of the specification. The disclosures of each of these publications, and also the disclosures of all patents, patent application publications and books recited herein, are hereby incorporated by reference in their entirety into the subject application to more fully describe the art to which the subject invention pertains.

IPC Classes  ?

• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis

Abstract

The present invention relates to methods and kits for detecting active tuberculosis infection in a subject using serological techniques and a first agent capable of binding an IgG, IgA and/or IgM directed to the first protein present in or on a Mycobacterium tuberculosis membrane vesicle or a Bacillus Calmette-Guerin (BCG) membrane vesicle. Also provided are methods of treating a subject with an active tuberculosis disease.

IPC Classes  ?

• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

Provided are method of synthesizing (R)-5-diphosphomevalonate (DPM), isopentenyl 5-pyrophosphase (IPP), dimethylallyl 5 -pyrophosphate (DMAPP) and isoprenoid using a one-pot synthesis.

IPC Classes  ?

• C12P 5/02 - Preparation of hydrocarbons acyclic
• C12P 5/00 - Preparation of hydrocarbons
• C12P 7/04 - Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic

Abstract

Methods and devices are disclosed for treating or preventing infections in a subject due to Pseudomonas aeruginosa using coformycin analogs and inhibitors of Pseudomonas aeruginosa 5'-methylthioadenosine deaminase (MTADA).

IPC Classes  ?

• A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
• C07H 19/00 - Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radicalNucleosidesMononucleotidesAnhydro derivatives thereof

Abstract

Provided are composition and methods for treating radiation-induced cell damage, and in particular aspects to methods for protecting, mitigating or otherwise treating radiation-induced induced depletion of tissue stem cells and injury to the supportive stem cell niche, and in even more particular aspects to methods for protecting, mitigating or otherwise treating radiation-induced gastrointestinal syndrome (RIGS), comprising sequential administration of a Wnt pathway activator/agonist (e.g., Rspo1 or a small molecule inducer thereof) that amplifies the surviving intestinal stem cell (ISC) pool post-radiation exposure, followed by a selective antagonist of the β-Catenin-CBP interaction (e.g., ICG-001 or other exemplary compounds disclosed herein) that accelerates differentiation of the stimulated (e.g., Rspo1-stimulated) ISC in crypt-villi axis, promoting villous regeneration and intestinal restitution, thereby mitigating RIGS. Adjunctive and combination therapy embodiments are encompassed.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H. pylori MTAN (5'-methylthioadenosine nucleosidase) to the subject.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

Methods and compositions are provided for inhibiting or treating a herpesvirus infection in a subject using inhibitors of mammalian Akt.

IPC Classes  ?

• A01N 37/18 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N, e.g. carboxylic acid amides or imidesThio-analogues thereof
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

A method of obtaining a population of PDGFRα+ CD51+ CD146high stem cells is provided. Compositions comprising PDGFRα+ CD51+ CD146hlgh stem cells, and methods of use of a population of PDGFRα+ CD51+ CD146high stem cells, are also provided.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor

Abstract

A composition is provided comprising an oligonucleotide aptamer conjugated to an antigen, wherein the aptamer is directed against a cell-surface target of an antigen- presenting cell. Also provided are methods of delivering an antigen to a dendritic cell and of eliciting an immune response in a subject.

IPC Classes  ?

• A61K 39/385 - Haptens or antigens, bound to carriers
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Methods are provided for producing differentiated cells from stem cells, including producing hepatocytes. Compositions thereof are also provided, as are methods of treating a liver disorder.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor

Abstract

Isolated mutant Mycobacterium tuberculosis bacteria comprising a deletion in the ESAT-6 gene cluster region 3 (esx-3 region) are provided, as well as compositions comprising such, methods of production thereof and methods of use thereof.

IPC Classes  ?

• A61K 39/02 - Bacterial antigens
• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material

Abstract

Nanoparticles are provided that comprise S-nitrosothiol (SNO) groups covalently bonded to the nanoparticles and/or S-nitrosothiol containing molecules encapsulated within the nanoparticles, as well as methods of making and using the nanoparticles. The invention also provides methods of preparing nanoparticles comprising Snitrosothiol (SNO) groups covalently bonded to the nanoparticles, where the methods comprise a) providing a buffer solution comprising chitosan, polyethylene glycol, nitrite, glucose, and hydrolyzed 3-mercaptopropyltrimethoxysilane (MPTS); b) adding hydrolyzed tetramethoxysilane (TMOS) to the buffer solution to produce a sol-gel; and c) lyophilizing and ball milling the sol-gel to produce nanoparticles of a desired size.

IPC Classes  ?

• A61K 31/04 - Nitro compounds

Abstract

Provided are methods of using humanin and humanin analogs to increase insulin secretion in a subject.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides

Abstract

Aptamers targeted to a human transferrin receptor which do not compete with transferrin for binding are provided. Compositions and methods for aptamer-targeted liposomal drug delivery are also provided.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• C40B 50/06 - Biochemical methods, e.g. using enzymes or whole viable microorganisms

Abstract

Methods and compositions are provided for diagnosing or inhibiting invasion or metastasis of a cancer in a subject based on MenaINV.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

A method of improving the efficacy of a blood transfusion into a subject is provided comprising administering a composition comprising an EAF PEGylated-blood protein into the subject, prior to, during, or subsequent to the blood transfusion.

IPC Classes  ?

• A61K 38/38 - Albumins
• A61K 38/42 - HaemoglobinsMyoglobins
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• C07K 14/805 - HaemoglobinsMyoglobins
• C07K 14/76 - Albumins
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid

Abstract

Methods and compositions are provided for treating HIV infection and for inhibiting HIV infection, and for identifying purinergic receptor antagonists or Panx 1 hemi-channel blockers useful therefor. The invention provides a method of treating a mammalian subject having an HIV infection, or suspected of having been exposed to HIV, comprising administering to the mammalian subject an amount of (i) an antagonist of a Panx 1 hemichannel, or (ii) of an inhibitor of a purinergic receptor, effective to inhibit (a) HIV fusion with a target cell, or (b) HIV replication, or (c) HIV entry into a target cell, or two or more of (a), (b) and (c).

IPC Classes  ?

• A61K 38/08 - Peptides having 5 to 11 amino acids

Abstract

The present invention provides methods for determining a putative agent that treats or prevents obesity and/or diabetes or increasing insulin sensitivity, the method comprising contacting cells with the putative agent and measuring thioredoxin-interacting protein (TXNIP) or thioredoxin expression or activity in the cells. The present invention also provides the agent, the pharmaceutical composition, and methods of preventing or treating obesity and/or diabetes or of increasing insulin sensitivity or glucose sensitivity, the method comprising administration of the agent that decreases the expression of TXNIP or activity of TXNIP.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Methods and systems for obtaining inhibitors of human immunodeficiency virus- 1 (HIV-1) protease are disclosed where the methods involve designing compounds that resemble the HIV-1 protease transition state.

IPC Classes  ?

• A01N 43/36 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings

Abstract

A method of detecting a microRNA present in a lung of a subject comprising amplifying, from a sample of exhaled breath condensate from the subject, a microRNA present therein by reverse transcription-polymerase chain reaction (RT-PCR) of the microRNA to corresponding DNA. Detection of pathogenic organisms or macromolecules in the lung are also encompassed.

IPC Classes  ?

• G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath

Abstract

Methods are provided of treating obesity or an obesity comorbidity in a mammalian subject comprising administering to the subject an amount of an agent effective to treat obesity or the obesity comorbidity, which agent inhibits (i) ΙκΒ kinase β (ΙΚΚβ) activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κΒ) or (ii) Notch signaling, in a manner so as to permit the agent to enter the hypothalamus of the subject. Assays are also provided for identifying candidate agents for treating obesity'.

IPC Classes  ?

• C12N 5/0797 - Stem cellsProgenitor cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Luciferase-linked methods for detecting adenosine and for screening for inhibitors of enzymes that produce adenosine are disclosed. The invention also provides methods for detecting the presence of Sadenosyl-L-homocysteine hydrolase (SAHH) comprising: (a) hydrolysis of S-adenosyl-Lhomocysteine (SAH) catalyzed by S-adenosyl-L-homocysteine hydrolase (SAHH) to adenosine and L-homocysteine; (b) converting adenosine to adenosine monophosphate (AMP) by adenosine kinase in the presence of a phosphate donor; (c) converting AMP to adenosine 5 '-triphosphate (ATP) by pyruvate phosphate dikinase (PPDK) in the presence of phosphoenolpyruvate (PEP) and inorganic pyrophosphate; and (d) reacting A TP with luciferin and Oz in the presence of luciferase to produce AMP and a luminescent signal, wherein the luminescent signal indicates the presence of S-adenosyl-L-homocysteine hydrolase (SAHH).

IPC Classes  ?

• C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving luciferase

Abstract

Antibodies to SEB, fragments thereof, and compositions comprising such are provided. Therapies for staphylococcal infection are provided, as well as assays for identifying additional agents useful in such therapies. An isolated antibody, or an isolated antigen-binding fragment of an antibody, is provided which antibody or antigen-binding fragment binds to staphylococcal enterotoxin B (SEB) and which antibody or antigen-binding fragment comprises a heavy chain variable CDR3 comprising the sequence RIYYGNNGGVMDY (SEQ ID N0:30); ARTAGLLAPMDY (SEQ ID N0:31); ARDTMRKCYCELKLKPPAEHPGPA (SEQ ID N0:32) or VRDL YGDYVGRY A Y (SEQ ID N0:48).

IPC Classes  ?

• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria

Abstract

Methods are disclosed for determining classification and prognosis of patients with diffuse large B-cell lymphoma (DLBCL) using activation of signal transducer and activator of transcription 3 (STAT3).

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)

Abstract

Antibodies to an amphiregulin neo-epitope, fragments thereof, and compositions comprising such are provided. Therapies for cancers in which cells thereof express amphiregulin are provided, as well as assays for identifying additional agents useful in such therapies.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12N 5/07 - Animal cells or tissues

Abstract

Methods are provided for treating Parkinson's disease, protecting dopaminergic neurons from neurotoxicity and for increasing DJ-1 levels in neruons. Methods are also provided for identifying candidate treatments for Parkinson's disease.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Methods are provided for detecting mycobacteria in a sample, including clinical samples. Methods are also provided for determining susceptibility of mycobacterial strains to known or potential antibiotic agents, as are kits therefor. Recombinant mycobacteriophages are also provided comprising heterologous nucleic acids of interest.

IPC Classes  ?

• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Abstract

Methods are provided for treating dementia and or impaired cognition, as well as assays useful for identifying novel anti-dementia agents. Compounds and compositions for treating dementia and or impaired cognition are also provided.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers

Abstract

A combination therapy to treat a cancer or a tumor is provided. A method of delaying resistance to an anti-cancer/anti-tumor therapy is also provided.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Abstract

Methods and products are provided for determining if a subject having a tumor is at risk of metastasis of the tumor. Specifically, the methods comprise detecting phosphorylated cofilin, and both phosphorylated and non-phosphorylated cofilin; quantifying the phosphorylated cofilin, and the total of phosphorylated and nonphosphorylated cofilin; and determining if a subject having the tumor is likely to experience metastasis of the tumor, based on the ratio of the amount of detected phosphorylated cofilin: total amount of phosphorylated and non-phosphorylated cofilin detected. Further disclosed are the types of tumor metastases that can be determined using the methods provided.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Methods are disclosed for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes using interleukin 1 receptor accessory protein and other targets.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Methods are provided for treating, mitigating or protecting from radiation-induced injury using bone marrow siromal cells expanded in culture, adipose-tissue derived non-adherent siromal cells, or ihe culture supernatant thereof.

IPC Classes  ?

• C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor

Abstract

Methods of treating a disease in a subject are provided comprising administering to the subject an amount of an agent which reduces, or prevents, interaction of a Gβγ with a pi 110β effective to treat the disease. Methods are also provided for identifying an inhibitor of interaction between a Gβγ and a ρ110β. Compositions are provided comprising a peptide comprising amino acid residues having the KAAEIASSDSANVSSRGGKKFLPV (SEQ ID NO:6).

IPC Classes  ?

• A61K 8/64 - ProteinsPeptidesDerivatives or degradation products thereof

Abstract

Methods are provided for determining if an agent causes somatic mutations in a genome, and kits, systems and computer-readable medium therefor.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers

Abstract

Methods and compositions for treating obesity or an obesity comorbidity in a subject are provided, employing an inhibitor of synaptotagmin-4 or an amount of oxytocin or an analogue thereof. Methods and compositions for effecting weight gain in a subject are also provided employing synaptotagmin-4, or an analogue of synaptotagmin-4, or an oxytocin antagonist.

IPC Classes  ?

• A61K 38/11 - Oxytocins; Vasopressins; Related peptides

Abstract

Methods and products are provided for determining if a subject having a tumor is (i) at risk of metastasis of the tumor, or (ii) at risk of recurrence of the tumor after treatment of the tumor. Methods of treatment of cancer, tumors and metastasis are also provided. Also provided is n method of determining a subject having a tumor as (i) at risk of metastasis of the tumor, (ii) at risk of invasion of the tumor, or (iii) at risk of recurrence of the tumor after treatment of the tumor, comprising obtaining a sample of the tumor and determining the level of expression in the sample of one or more of the genes (I) in the upregulated DNA Replication and Repair section of Table 1; (2) in the upregulated Embryonic and Tissue Development section of Table I; (3) in the upregulated Cellular Movement and Development section of Table I; (4) in the upregulated Cell-to-Cell Signaling and interaction section of Table I; and/or (5) in the upregulated Cellular Assembly and Organization section of Table I.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The invention relates to compounds of formula (I) that are inhibitors of hypoxanthine and/or guanine purine phosphoribosyltransferases and to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to inhibit hypoxanthine and/or guanine purine phosphoribosyltransferases. Such diseases include malaria.

IPC Classes  ?

• C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
• C07D 487/04 - Ortho-condensed systems
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61P 33/06 - Antimalarials

Abstract

Methods are provided for treating a cancer in a subject comprising administering to the subject an agent which inhibits expression of an HLX gene in the subject, or an agent which inhibits activity of an expression product of the HLX gene, and also for diagnosing a subject as likely to develop a cancer comprising determining whether a stem cell obtained from the subject expresses a HLX gene at a level in excess of predetermined control level. Kits therefor are also provided.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

Methods are provided for treating metastatic cancer in patients having metastatic cancer or for preventing metastasis in cancer patients at risk for metastasis comprising administering to the patient an antibody to B7x, or an active antibody fragment that binds B7x, in an amount effective to treat or prevent metastasis.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The present invention provides methods of inhibiting angiogenesis in a malignant tumor, inhibiting metastasis of a malignant tumor and of inhibiting transformation of a benign tumor to a malignant tumor. The present invention also provides assays for identifying inhibitors of angiogenesis in a malignant tumor, inhibitors of metastasis of a malignant tumor and of inhibitors of transformation of a benign tumor to a malignant tumor.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 14/505 - Erythropoietin [EPO]
• A61P 35/00 - Antineoplastic agents

Abstract

Methods and compositions are provided for alleviating and/or preventing one or more side effects associated with exposure to radiation in a subject exposed to radiation or at risk for exposure to radiation comprising oral administration to the subject of an amount of an edible source of melanin effective to alleviate a side effect associated with radiation.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders

Abstract

The present invention provides compositions and methods for treating obesity in a subject by administering an inhibitor of UBE2L6 or an activator of adipocyte triglyceride lipase to the subject.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers

Abstract

The present invention provides a method for identifying a tumor as likely to metastasize, or likely to have metastasized, comprising obtaining a sample of the tumor and quantitating alternatively spliced mRNA isoforms of a cell motility gene, a cell adhesion gene and /or an actin cytoskeletal remodeling gene in the sample, or any specified genes or the level of RNA binding proteins compared to a predetermined non-metastasizing control.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

A method of treating a tumor in a subject, or reducing or preventing metastasis of a tumor in a subject, is provided comprising administering to the subject an amount of a bacteria labelled with, or comprising, one or more radionuclides so as to treat the tumor in the subject, or so as to reduce or prevent metastasis of the tumor in the subject. Radiobacteria-containing compositions and pharmaceutical compositions are also provided.

IPC Classes  ?

• A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo
• A61M 36/14 - Radioactive dressings

Abstract

The present invention provides resveratrol-based boron-containing analog! methods of use thereof in treatment of dyslipidemias and cancer.

IPC Classes  ?

• A01N 55/08 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur containing boron
• A61K 31/69 - Boron compounds

Abstract

Methods and assays for treating a subject with a filovirus infection using an agent that inhibits Niemann-Pick CI (NPCI), VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4. Methods for screening for an agent that treats and/or prevents infection of a subject with a filovirus, where the methods comprise determining whether the agent inhibits one or more of Niemann-Pick CI (NPCI), VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41. BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4, wherein an agent that inhibits one or more of NPCI, VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4 is a candidate for treating and/or preventing an infection with a filovirus and wherein an agent that does not inhibit NPCI, VPSII, VPSI6, VPSI8, VPS33A. VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4 is not a candidate for treating and/or preventing an infection with a filovirus.

IPC Classes  ?

• A61K 39/12 - Viral antigens

Abstract

Nucleic acid constructs for expressing an antibody on the surface of bacteriophage are disclosed, as are methods for using the constructs to identify antibodies that target glycans. The present invention provides nucleic acid constructs comprising Hindlll (AAGCTT), 2GI2 VL (SEQ ID NO:l), CL (SEQ ID NO:2), Intragenic region (SEQ ID NO:3), pel B (SEQ ID NO:4), Region X (SEQ ID 5), spe I (ACTAGT), VH (SEQ ID NO:6), CH (SEQ ID NO:7), Hinge (SEQ ID NO:8), GCN4 (SEQ ID NO:9), and Sail (GTCGAC), or a modified version thereof wherein the modification consists of one or more modification in the sequence of the 2GI2 VL region and/or on or more modification in the sequence of the VH region, and wherein the modification consists of a substitution of one codon for another codon, up to nine such substitutions, and/or insertion of up to nine additional codons.

IPC Classes  ?

• C40B 40/08 - Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries

Abstract

The present invention discloses methods for treating bacterial infections in a subject comprising administering to the subject a sub-growth inhibiting amount of a 5'- methylthioinosine phosphorylase (MTIP) inhibitor, as well as assays for identifying such inhibitors, and compounds and pharmaceutical compositions comprising the inhibitors.

IPC Classes  ?

• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole

Abstract

Methods and apparatus are disclosed for imaging molecular interactions in living cells at high resolution, low light levels and high acquisition speeds.

IPC Classes  ?

• G01N 33/559 - ImmunoassayBiospecific binding assayMaterials therefor using diffusion or migration of antigen or antibody through a gel, e.g. Ouchterlony technique

Abstract

Disclosed are tris(triazolylmethyl)amine ligands, and kits and methods for labeling and/or imaging a biomolecule of interest in a subject or living system.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The invention is directed compositions and methods related to bacterial cells that are physically associated with ceramide-like glycolipids for use as antigen carriers for heterologous antigens. The invention further relates to methods of incorporating ceramide-like glycolipid to bacterial cell walls. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.

IPC Classes  ?

• C12N 1/12 - Unicellular algaeCulture media therefor

Abstract

The present invention provides methods of preventing or inhibiting tumor metastasis in a subject by administering a therapeutically effective amount of (1) a compound from a group of enumerated compounds, or a pharmaceutically acceptable salt thereof; (2) an agent that covalently modifies at least one cysteine residue of S100A4 protein; or (3) an agent that inhibits the interaction between S100A4 and myosin-IIA.

IPC Classes  ?

• A01N 43/42 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings

Abstract

The present invention provides methods of preparing an oligonucleotide, nucleoside or nucleoside analog for selective introduction into a subject's cells, the method comprising (1) selecting a targeted aptamer, internalizing nucleic acid or tumor-homing nucleic acid via iterative rounds of selection, and (i) hybridizing it to an oligonuceotide, (ii) replacing one or more nucleotide with a nucleoside or nucleoside analog, or (iii) synthesizing the it with one or more nucleoside or nucleoside analogs; or (2) preparing a naive combinatorial aptamer, internalizing nucleic acid or tumor-homing nucleic acid prodrug library, and running iterative rounds of selection for the cells. The present invention also provides the agent, the pharmaceutical composition, and methods of treating or preventing cancer and/or viral infection, the method comprising administration of the oligonuleotide, nucleoside or nucleoside analog for selective introduction into a subject's cells.

IPC Classes  ?

• C40B 50/06 - Biochemical methods, e.g. using enzymes or whole viable microorganisms
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Abstract

The present invention provides methods for determining a putative agent that treats or prevents obesity and/or diabetes or increasing insulin sensitivity, the method comprising contacting cells with the putative agent and measuring thioredoxin-interacting protein (TXNIP) or thioredoxin expression or activity in the cells. The present invention also provides the agent, the pharmaceutical composition, and methods of preventing or treating obesity and/or diabetes or of increasing insulin sensitivity or glucose sensitivity, the method comprising administration of the agent that decreases the expression of TXNIP or activity of TXNIP.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/28 - Insulins
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 7/12 - Antidiuretics, e.g. drugs for diabetes insipidus

Abstract

Disclosed are Na+/I- symporter (NIS) mutant proteins wherein glycine residue 93 is replaced with aspartic acid or glutamic acid, a method of preparing said mutant NIS protein, a transfection vector for a NIS mutant protein, and a pharmaceutical composition comprising said mutant NIS protein in a pharmaceutically acceptable carrier. The disclosure also provides a method of treating cancer or cancerous cells, comprising administering a therapeutically effective amount of a transfection vector for a NIS mutant protein or a pharmaceutical composition thereof, and administering a therapeutically effective amount of radioisotope. The disclosure further provides a method of imaging cells, comprising administering to the cells an effective amount of a transfection vector for a NIS mutant protein, administering a effective amount of imaging label, and imaging the cells.

IPC Classes  ?

• C07K 1/00 - General processes for the preparation of peptides
• A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

The present invention provides methods for determining if an agent (i) treats or prevents cancer, (ii) treats or prevents obesity, and/or (iii) increases insulin sensitivity, comprising contacting Fyn and /or LKB1 with the agent and determining if the agent inhibits Fyn kinase activity or inhibits the interaction between Fyn and LKB1, wherein inhibition of Fyn kinase activity or inhibition of the interaction between Fyn and LKB1 by the agent indicates that the agent (i) treats or prevents cancer, (ii) treats or prevents obesity, and/or (iii) increases insulin sensitivity. The present invention also provides methods for treating cancer, treating obesity, or increasing insulin sensitivity in a subject, comprising administering to the subject a therapeutically effective amount of an agent that inhibits Fyn kinase or that inhibits the interaction between Fyn and LKB1.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• A61K 38/45 - Transferases (2)

Abstract

The present invention relates to methods for detecting the activity of DNA (cytosine 5)-methyltransferase, protein methyltransferase or any enzyme that forms S-adenosyl-l- homocysteine (AdoHcy) as a product, and for screening for inhibitors of DNA (cytosine 5)- methyltransferase, protein methyltransferase and any enzyme that forms S-adenosyl-l- homocysteine (AdoHcy) as a product using luciferase-linked assays that convert the S- adenosyl-l-homocysteine (AdoHcy) product to a quantifiable luminescent signal.

IPC Classes  ?

• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions

Abstract

The present invention provides quantitative methods for the detection of tau protein and/or tau fragments. More specifically, the present invention provides quantitative methods for diagnosing a tauopathy or ruling out a tauopathy as the cause of disease, particularly the diagnosis and ruling of Alzheimer's disease. The present invention further provides a method for diagnosing a tauopathy by computing the ratio of two detected tau proteins or tau fragments.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Abstract

The present invention provides an albumin polymer and a process of making an albumin polymer, the process comprising breaking instrinsic disulfide bridges in albumin with a reducing agent and crosslinking inter- and intra- molecular disulfide bridges so as to form the ploymer. The present invention also provides PEGylated albumin polymers and methods of making PEGylated albumin polymers, the methods comprising polymerizing albumin by crosslinking inter- and intra- molecular disulfide bridges, and PEGylating the albumin polymer. The present invention further provides a pharmaceutical composition useful as a blood plasma expander, blood substitute or for drug delivery, and methods of treating blood loss in a subject and of delivering drugs to a subject's tissue, the pharmaceutical composition comprising a therapeutically effective amount of the PEGylated albumin polymer.

IPC Classes  ?

• A61K 38/38 - Albumins
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

The present invention provides methods of treating hemophilia in a subject, the methods comprising transplanting a therapeutically effective amount of bone marrow, cord blood, cord blood or bone marrow fraction expressing Factor VIII, mononuclear cells, or mesenchymal stromal cells from a donor to the subject with hemophilia. The present invention also provides compositions for treating hemophilia.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The present invention provides methods to prevent or treat flavivirus infection, and assays for identifying agents which treat flavivirus infection. The present invention also provides compositions for preventing flavivirus infection and a kit for screening an agent that prevents or treats viral infection.

IPC Classes  ?

• A61K 38/10 - Peptides having 12 to 20 amino acids

Abstract

The present invention relates to methods of determining agents that inhibit Mena+ or MenaINV/+, and uses of agents that bind to and/or inhibit Mena+ or MenalNV/+ for diagnosis and treatment of metastatic tumors.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The present invention provides a method of isolating motile cells from an animal tissue, the method comprising implanting in the animal tissue a cell trap comprising a chamber with an inlet for ingress of motile cells and a porous matrix located in the chamber comprising a chemotactic factor, for a time sufficient for the motile cells to migrate into the cell trap; removing the implanted cell trap; and retrieving the motile cells from the cell trap.

IPC Classes  ?

• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

Compounds, compositions and methods are provided that comprise selective β-glucuronidase inhibitors for both aerobic and anaerobic bacteria, especially enteric bacteria normally associated with the gastrointestinal tract. The compounds, compositions and methods can be for inhibiting bacterial β-glucuronidases and for improving efficacy of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds by attenuating the side effects caused by reactivation by bacterial β-glucuronidases of glucuronidated metabolites of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds.

IPC Classes  ?

• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• A61K 31/38 - Heterocyclic compounds having sulfur as a ring hetero atom
• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin

Abstract

The present invention provides a device for immobilizing aquatic animals, the device comprising a receptacle for holding an aquatic animal in a volume of water, an opening in the receptacle for placement and removal of the aquatic animal, a restraint positioned inside the receptacle for restraining the aquatic animal, and a tube attached to the receptacle for supplying air or aerated water to the receptacle. The present invention further provides methods of immobilizing and imaging live aquatic animals using the device of the present invention.

IPC Classes  ?

• A01K 63/00 - Receptacles for live fish, e.g. aquariaTerraria

Abstract

The present invention provides methods and kits for determining which microRNAs bind to a target mRNA where the methods comprise the steps of (a) creating a bait sequence from the target mRNA, where the bait sequence comprises a label that binds to a binding agent; (b) adding a mixture of microRNAs to the bait sequence; (c) separating the microRNAs that bind to the bait sequence from those microRNAs that do not bind; and (d) identifying the microRNAs that bind to the bait sequence, wherein the microRNAs identified are those that bind to the target mRNA.

IPC Classes  ?

• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Abstract

Disclosed are compounds for inhibiting prostaglandin transporter (PGT) activity, pharmaceuticals compositions including the compounds, and methods of treating subjects using the compounds.

IPC Classes  ?

• A01N 43/66 - 1,3,5-Triazines, not hydrogenated and not substituted at the ring nitrogen atoms
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

Abstract

The present invention provides a method for determining a putative agent that inhibits the SUMO or the SUMO-targeted ubiquitin ligase pathway comprising the steps of contacting mutant MOT1 cells with the putative agent under conditions (1) permitting mutant MOT1 cell growth in the presence of a SUMO or SUMO-targeted ubiquitin ligase pathway inhibitor and (2) not permitting mutant MOT1 cell growth in the absence of a SUMO or SUMO-targeted ubiquitin ligase pathway inhibitor, and measuring cell growth.

IPC Classes  ?

• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

Disclosed are methods of improving motor functions of a subject by administering cognitive function training to the subject. The cognitive functions trained can include executive and/or attention functions. The improved motor functions can be, for example, one or more of improved gait, increased speed of walking, increased speed of walking while talking, and decreased incidence of falling.

IPC Classes  ?

• G09B 19/00 - Teaching not covered by other main groups of this subclass

Abstract

Disclosed are methods for determining whether a subject may have hepatic insulin resistance, for diagnosing hepatic insulin resistance, and for assessing the prognosis of a subject with hepatic insulin resistance, comprising determining the level of expression of major facilitator superfamily domain 2 protein (Mfsd2) in a subject's liver, where overexpression of Mfsd2 is indicative of hepatic insulin resistance.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

Disclosed are methods for treating liver failure in a subject comprising transplanting hepatocytes or stem or progenitor cells in an extrahepatic site in the subject in an amount sufficient to provide liver support and/or induce liver regeneration, where the transplanted hepatocytes or stem or progenitor cells are used along with extracellular matrix-coated microcarriers.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

The invention provides compositions for controlled delivery and/or containment of therapeutic and/or diagnostic agents comprising the agent or agents encapsulated by a matrix containing chitosan, polyethylene glycol (PEG) and/or polyvinyl alcohol (PVA), and tetra- methoxy-ortho-silicate (TMOS) or tetra-ethoxy-ortho-silicate (TEOS), as well as methods for preparing the compositions, and uses of the compositions for therapy and imaging.

IPC Classes  ?

• A61K 9/22 - Sustained or differential release type

Abstract

The present invention relates to inhibitors of mitochondria-associated, granulocyte- macrophage colony stimulating factor signaling molecule (Magmas), and related compositions and uses thereof.

IPC Classes  ?

• A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof

Abstract

The present invention is directed to methods for evaluating the efficacy of a cancer treatment for (i) inhibiting metastasis in a subject, (ii) inhibiting local cancer cell movement, and (iii) inhibiting cancer cell proliferation. The present invention is further directed to methods for monitoring cell motility in a subject. The present invention is also directed to kits for performing any of the above methods.

IPC Classes  ?

• C12N 5/07 - Animal cells or tissues
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper

Abstract

The invention is directed compositions and methods related to bacterial cells physically associated with ceramide-like glycolipids. The invention allows for delivery of ceramide-like glycolipid adjuvants directly to the same cells that become infected with a bacterial vaccine. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.

IPC Classes  ?

• C12N 1/12 - Unicellular algaeCulture media therefor
• C12N 1/20 - BacteriaCulture media therefor
• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis

Abstract

Disclosed are PEGylated hemoglobins (Hbs) modified at Valine-1 (alpha) to increase tetramer stability of hemoglobin, methods of making these modified hemoglobins, and their use as blood substitutes.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

Methods are provided for designing a transition state inhibitor of orotate phosphoribosyltransferase (OPRT) and for inhibiting OPRT.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology

Abstract

The present invention generally relates to oxazine derivative compounds and related compositions and methods for inducing hypoxic tumor cell death, treating cancer and locating a hypoxic tumor in a subject.

IPC Classes  ?

• A61K 31/535 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

Abstract

The present invention is directed to methods for detecting the presence of ricin and compounds that catalyze the release of adenine from nucleic acids or other biological materials and for screening for inhibitors of such compounds.

IPC Classes  ?

• C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
• C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving luciferase

Abstract

The present invention provides methods for treating bacterial infections in a subject comprising administering to the subject a sub-growth inhibiting amount of a 5'-Methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) inhibitor. The present invention further provides pharmaceutical compositions comprising a sub-bacterial-growth inhibiting amount of a 5'-Methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) inhibitor and a pharmaceutically acceptable carrier.

IPC Classes  ?

• A01N 43/36 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Abstract

The present invention generally relates to an apparatus for structural mapping of a macromolecule comprising an amount of persulfide effective to generate hydroxyl radicals upon contact with an aqueous solution. The present invention further relates to methods for structural mapping a macromolecule in an aqueous solution and methods for structural mapping a plurality of macromolecules in parallel, wherein each macromolecule is in a separate aqueous solution.

IPC Classes  ?

• G06G 7/48 - Analogue computers for specific processes, systems, or devices, e.g. simulators
• G06G 7/58 - Analogue computers for specific processes, systems, or devices, e.g. simulators for chemical processes

Abstract

Methods are disclosed for using agents and treatments that cause the release of melanin from melanin-containing melanomas to increase the efficacy of therapy and imaging of the melanomas with radiolabeled anti-melanin antibodies and peptides.

IPC Classes  ?

• A61K 31/415 - 1,2-Diazoles

Abstract

The invention is directed to a compound that binds to a BCL6 lateral groove and prevents binding of a corepressor to the lateral groove. The present invention is further directed to methods for blocking corepressor binding to a BCL6 lateral groove, methods for inhibiting BCL6 repression in a mammalian cell, and methods for treating a mammal with cancer, wherein the cancer requires BCL6 repression. The present invention is further directed to polypeptides comprising a portion of the corepressor binding site for BCL6 and related polynucleotides and vectors.

IPC Classes  ?

• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor